Billiontoone, Inc. (NASDAQ:BLLN – Get Free Report) SVP Bosch John Roderick Ten sold 1,417 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $92.86, for a total value of $131,582.62. Following the completion of the sale, the senior vice president directly owned 27,884 shares of the company’s stock, valued at approximately $2,589,308.24. This trade represents a 4.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Bosch John Roderick Ten also recently made the following trade(s):
- On Monday, June 29th, Bosch John Roderick Ten sold 1,416 shares of Billiontoone stock. The shares were sold at an average price of $120.00, for a total value of $169,920.00.
- On Monday, June 15th, Bosch John Roderick Ten sold 2,832 shares of Billiontoone stock. The shares were sold at an average price of $101.47, for a total value of $287,363.04.
Billiontoone Stock Down 0.5%
NASDAQ:BLLN traded down $0.49 during trading hours on Wednesday, hitting $97.45. 522,419 shares of the company traded hands, compared to its average volume of 537,016. The company has a quick ratio of 11.31, a current ratio of 11.69 and a debt-to-equity ratio of 0.17. The company has a market cap of $4.48 billion and a PE ratio of 139.21. The firm’s 50-day simple moving average is $116.72 and its 200-day simple moving average is $94.50. Billiontoone, Inc. has a one year low of $61.96 and a one year high of $150.44.
Analysts Set New Price Targets
Several equities research analysts have commented on BLLN shares. Weiss Ratings upgraded shares of Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday, June 23rd. Wall Street Zen lowered Billiontoone from a “buy” rating to a “hold” rating in a report on Saturday. Guggenheim began coverage on Billiontoone in a research report on Monday, June 29th. They set a “buy” rating and a $125.00 price target for the company. JPMorgan Chase & Co. dropped their price target on Billiontoone from $145.00 to $130.00 and set an “overweight” rating on the stock in a report on Thursday, August 6th. Finally, BTIG Research cut their price objective on Billiontoone from $142.00 to $130.00 and set a “buy” rating on the stock in a research report on Thursday, August 6th. Six equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $126.71.
Institutional Investors Weigh In On Billiontoone
Several large investors have recently modified their holdings of the stock. Rossby Financial LCC purchased a new position in Billiontoone in the fourth quarter valued at approximately $25,000. Wells Fargo & Company MN bought a new stake in shares of Billiontoone in the fourth quarter valued at $76,000. Smartleaf Asset Management LLC bought a new stake in shares of Billiontoone in the fourth quarter valued at $80,000. Nano Cap New Millennium Growth Fund L P purchased a new position in shares of Billiontoone during the 4th quarter valued at $82,000. Finally, Renaissance Capital LLC purchased a new position in shares of Billiontoone during the 4th quarter valued at $201,000.
Billiontoone Company Profile
BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.
BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.
Read More
- Five stocks we like better than Billiontoone
- GE Vernova’s AI Power Boom Faces a Profit Test
- Cardinal Health Earnings: Can Perfection Get Priced In Twice?
- Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand
- Legacy Jet Builders Stall While Embraer Accelerates to New Highs
Receive News & Ratings for Billiontoone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Billiontoone and related companies with MarketBeat.com's FREE daily email newsletter.
